Jiangxi Rimag Group Co., Ltd. 江西一脈陽光集團股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2522） 關於授予H股獎勵股份的方案 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容所產生或因依 賴該等內容而引致的任何損失承擔任何責任。 茲提述江西一脈陽光集團股份有限公司（「本公司」，連同其附屬公司統稱「本集 團」）日期分別為2024年9月30日及2024年10月21日的公告（「該等公告」），以及日 期為2024年10月4日的通函（「該通函」），內容有關（其中包括）採納以現有股份償 付之股份獎勵計劃（「股份獎勵計劃」）。除另有界定者外，本公告所用詞彙與該等 公告及該通函所界定者具有相同涵義。 本公司董事（「董事」）會（「董事會」）宣佈，本公司擬根據股份獎勵計劃的條款及 條件及個人考評結果向本次選定激勵對象（「激勵對象」）授予H股獎勵股份（「本次 授予」）。具體授予方案如下： 授予方案 激勵對象：本次授予的激勵對象包括本公司4名董事（即陳朝陽先生、何英飛女 ...

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical industry [3] Core Insights - The pharmaceutical and biotechnology index decreased by 0.68% this week, underperforming the CSI 300 index by 0.11 percentage points, ranking 19th in industry performance [12] - The healthcare sector has shown significant growth, with the medical services sub-sector increasing by 16.04% year-to-date, while traditional Chinese medicine has the lowest growth at 1.86% [17][19] - The J.P. Morgan Health Conference highlighted the strategic advancements of top global pharmaceutical companies, with over 20 Chinese firms participating, indicating a trend towards overseas collaboration in innovative drugs [34] Summary by Sections Market Review - The pharmaceutical index has risen by 7.08% from the beginning of 2026 to January 16, outperforming the CSI 300 index by 4.88 percentage points, ranking 8th in industry performance [12] - The medical services sub-sector has the highest year-to-date growth at 16.04%, while the lowest is traditional Chinese medicine at 1.86% [19] Individual Stock Performance - In the A-share market, 206 out of 478 pharmaceutical stocks rose, with the top five performers being Baolait (up 48.76%), Hualan Biological (up 32.72%), and Tianzhihang (up 27.67%) [23] - In the Hong Kong market, 59 out of 116 pharmaceutical stocks increased, with Ark Health leading at 51.66% growth [26] Industry News and Policies - The sixth batch of national high-value medical consumables procurement was opened on January 13, with 202 companies winning bids for 440 products [29] - Medtronic announced a strategic partnership with Precision Neuroscience to develop integrated solutions combining their technologies [29] - Boston Scientific plans to acquire Penumbra for approximately $14.5 billion, enhancing its portfolio in peripheral vascular interventions [30] Weekly Insights - The medical services sector's strong performance is attributed to positive revenue growth, with medical commercial and services sectors showing year-on-year revenue increases of 0.56% and 3.99%, respectively [33] - The J.P. Morgan Health Conference served as a significant platform for discussing trends in drug development and investment strategies, with a focus on AI and international collaborations [34]

Core Insights - The article highlights the changes in the Hong Kong Stock Connect holdings, indicating significant increases and decreases in ownership percentages for various companies [1][2]. Group 1: Companies with Increased Holdings - Baidu's subsidiary, 百奥赛图-B (02315), saw an increase of 1.90%, bringing its latest holding percentage to 17.59% [2]. - 昭衍新药 (06127) experienced a 1.57% increase, with a current holding of 62.66% [2]. - 广和通 (00638) had a 1.49% increase, resulting in a holding of 13.68% [2]. - 钧达股份 (02865) increased by 1.40%, now holding 36.52% [2]. - 纳芯微 (02676) saw a 0.90% increase, with a holding of 9.00% [2]. Group 2: Companies with Decreased Holdings - 狮腾控股 (02562) experienced the largest decrease at -8.40%, with a current holding of 47.81% [2]. - 昊天国际建投 (01341) decreased by -3.13%, now holding 59.69% [2]. - 一脉阳光 (02522) saw a reduction of -1.19%, with a holding of 44.02% [2]. - 中国中免 (01880) decreased by -1.17%, now at 38.19% [2]. - 弘业期货 (03678) had a decrease of -1.16%, with a holding of 60.67% [2]. Group 3: Five-Day Changes in Holdings - 钧达股份 (02865) had the highest increase over five days at +8.32%, with a holding of 36.52% [3]. - 纳芯微 (02676) increased by +7.60%, now at 9.00% [3]. - 中伟新材 (02579) saw a +6.19% increase, with a holding of 11.83% [3]. - 昭衍新药 (06127) increased by +5.03%, holding 62.66% [3]. - 佑驾创新 (02431) had a +3.96% increase, now at 11.83% [3]. Group 4: Twenty-Day Changes in Holdings - 狮腾控股 (02562) had a significant increase of +12.54%, with a holding of 47.81% [4]. - 南京熊猫电子股份 (00553) increased by +9.81%, now at 50.06% [4]. - 均胜电子 (00699) saw a +9.02% increase, with a holding of 15.26% [4].

Core Viewpoint - The company, Yipai Yangguang (02522.HK), has announced the approval of a special resolution to abolish the supervisory board and amend its articles of association, effective from January 13, 2026 [1] Group 1 - The shareholders approved the special resolution at the extraordinary general meeting [1] - The supervisory board will no longer be established from January 13, 2026, and current members will cease to hold their positions [1] - The amended articles of association and its attachments will take effect from the date of the extraordinary general meeting [1]

江西一脈陽光集團股份有限公司 章 程 | 第一章 | 總則 | 1 | | --- | --- | --- | | 第二章 | 經營宗旨和範圍 | 2 | | 第三章 | 股份 | 3 | | 第一節 | 股份發行 | 3 | | 第二節 | 股份增減和回購 | 7 | | 第三節 | 股份轉讓 | 9 | | 第四章 | 股東和股東會 | 10 | | 第一節 | 股東 | 10 | | 第二節 | 股東會的一般規定 | 14 | | 第三節 | 股東會的召集 | 17 | | 第四節 | 股東會的提案與通知 | 18 | | 第五節 | 股東會的召開 | 20 | | 第六節 | 股東會的表決和決議 | 23 | | 第五章 | 董事會 | 29 | | 第一節 | 董事 | 29 | | 第二節 | 董事會 | 33 | | 第三節 | 專門委員會 | 38 | | 第六章 | 總經理及其他高級管理人員 | 39 | | 第七章 | 財務會計制度、利潤分配和審計 | 41 | | 第一節 | 財務會計制度 | 41 | | 第二節 | 內部審計 | 42 | | 第三節 | 會計師事務所的聘任 | 43 ...

於2026年1月13日舉行之臨時股東會投票表決結果；及 取消監事會並修訂《公司章程》及其附件 江西一脈陽光集團股份有限公司（「本公司」）董事會（「董事會」）欣然宣佈於2026 年1月13日（星期二）上午十時正透過網上虛擬會議的方式舉行之臨時股東會（「臨 時股東會」）投票表決結果。 茲提述臨時股東會通告及本公司日期為2025年12月23日的通函（「該通函」）。除另 有所指外，本公告所用詞彙與該通函所界定者具有相同涵義。 臨時股東會投票表決結果 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容所產生或因依 賴該等內容而引致的任何損失承擔任何責任。 Jiangxi Rimag Group Co., Ltd. 江西一脈陽光集團股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2522） 取消監事會並修訂《公司章程》及其附件 股東於臨時股東會上通過特別決議批准取消監事會並修訂《公司章程》及其附件。 因此，自2026年1月13日起，本公司不再設監事會，現任監事會成員不再擔任監 事及監事會相關職務； ...

Group 1 - The core point of the article highlights that southbound funds increased their holdings in Yipai Sunshine (02522.HK) by 1.022 million shares on January 8, while experiencing a net reduction of 0.887 million shares over the last five trading days [1] - Over the past 20 trading days, Yipai Sunshine faced net reductions in holdings for 10 days, totaling 3.7445 million shares [1] - Currently, southbound funds hold 13.3 million shares of Yipai Sunshine, representing 45.1% of the company's total issued ordinary shares [1] Group 2 - Yipai Sunshine Group Co., Ltd. is primarily engaged in specialized medical imaging services in China [1] - The company offers medical imaging services and solutions through three main divisions: imaging center services, imaging solutions, and Yipai cloud services [1] - The imaging center services provide diagnostic imaging examinations to patients and healthcare consumers, while imaging solutions assist hospitals in selecting and procuring suitable imaging equipment [1]

Core Viewpoint - The company Yipai Yangguang (02522) announced a share buyback plan, indicating confidence in its stock value and future prospects [1] Group 1: Share Buyback Details - The company will repurchase 255,500 shares at a total cost of HKD 1.9923 million [1] - The buyback price per share ranges from HKD 7.71 to HKD 7.87 [1]

Group 1 - The company, Yipai Sunshine (02522), announced a share buyback plan [1] - The total amount spent on the buyback is HKD 1.9923 million [1] - The company will repurchase 255,500 shares at a price range of HKD 7.71 to HKD 7.87 per share [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 江西一脈陽光集團股份有限公司 呈交日期： 2026年1月8日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02522 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | | 佔有 ...